Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of TNGX is 16 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell